The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect

Viruses Pub Date : 2024-09-03 DOI:10.3390/v16091409
Dilan Cin, Pinar Soguksu, Meryem Merve Oren, Nuray Ozgulnar, Ali Agacfidan, Sevim Mese
{"title":"The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect","authors":"Dilan Cin, Pinar Soguksu, Meryem Merve Oren, Nuray Ozgulnar, Ali Agacfidan, Sevim Mese","doi":"10.3390/v16091409","DOIUrl":null,"url":null,"abstract":"Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (n = 60) and Vaccinated + Previously Infected (n = 60). A commercial sVNT, the ACE2–RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups (p < 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.","PeriodicalId":501326,"journal":{"name":"Viruses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/v16091409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (n = 60) and Vaccinated + Previously Infected (n = 60). A commercial sVNT, the ACE2–RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups (p < 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.
在有 COVID-19 疫苗接种史和/或 SARS-CoV-2 感染史的人群中使用化学发光微粒子免疫测定 (CMIA) 检测的抗 SARS-CoV-2 S 蛋白 IgG 显示出高滴度中和效应
中和抗体通过阻止严重急性呼吸系统综合症冠状病毒-2(SARS-CoV-2)进入细胞,在保护性免疫中发挥着主要作用。因此,抗病毒免疫的特征对于保护机体免受 SARS-CoV-2 感染非常重要。在本研究中,使用基于化学发光微粒子免疫测定(CMIA)的 SARS-CoV-2 IgG II Quant(Abbott, Waukegan, IL, USA)检测方法对 SARS-CoV-2 感染者和/或疫苗接种者的抗 SARS-CoV-2 S1 蛋白 IgG 的中和作用进行了替代病毒中和试验(sVNT)的研究。本研究共纳入 120 名血清反应阳性者。他们被分为两组:接种疫苗组(n = 60)和接种疫苗 + 曾受感染组(n = 60)。评估中和效果时使用了一种商用 sVNT,即 ACE2-RBD 中和试验(意大利米兰 Dia.Pro)。检测分两步进行:筛选和滴定。筛查结果显示,所有血清阳性样本均呈阳性。根据 ACE2-RBD 滴定试验的结果,接种疫苗组有 1.7%的人低滴定,5%的人中滴定,93.3%的人高滴定;另一组有 1.7%的人中滴定,98.3%的人高滴定。两组的 SARS-CoV-2 IgG II 定量测试和 ACE2-RBD 滴定测试在 1/32 滴定水平上都发现了很强的正相关性和显著性(两组的相关性均为 p <0.001)。这项研究表明,在 SARS-CoV-2 感染和/或接种疫苗后,使用 CMIA 方法检测到的 SARS-CoV-2 IgG 具有较高的中和滴定能力。根据这些数据,CMIA 检测出的血清阳性也表明具有很强的中和作用,这一知识有助于在全国范围内制定保护人口的计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信